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Sir, 
The current management of Antiphosphospholipid Syndrome (APS) centres on attenuating 
thepro-coagulant state while balancing the haemorrhagic risks[1]. This approach relies 
mainly on a thrombo-prophylaxisstrategy rather than targeting pathogenic antiphospholipid 
antibodies (aPL)-mediated pathways. 
Herewith, we report the aPLdisappearance in three patients with APS associated to Systemic 
Lupus Erythematous (SLE) while on treatment with belimumab, potentially paving the way 
for development of new targeted therapies for APS. Belimumab is a monoclonal antibody 
that works by blocking the B-lymphocyte stimulator and avoiding  B-cell activation[2].It is 
the first biological drug approved for the treatment of autoantibody positiveSLE in active 
phase, and it has shown its capability to reduce the antibodies levels, including  anti-double 
stranded-DNA[3]. Intriguingly, in murine models of APS in the setting of SLE, Belimumab 
proved its ability to stop disease progression and to reduce mortality rate [4].  However, its 
use in APS patients needs further investigation. 
After chart-reviewing all the aPL-positive SLE patients treated in our centre with belimumab, 
investigating the changes in the aPL profile, we identified three patients with diagnosis of 
SLE[5] and APS (fulfilling Sydney classification criteria)[6] and persistent aPL positivity 
(confirmed in more than 6 occasions over the previous 5 years before starting Belimumab) 
in whom we observed aPL disappearance. Clinical characteristics are detailed in Table 1 and 
aPL testing methodology is detailed in Supplementary Material S1. All patients received 
belimumab for active SLE (i.v.10 mg/kg at 2-week intervals for the first 3 doses and at 4-
week intervals thereafter). After 8 months since belimumab was started, Patient#1 became 
persistently negative for anti-β2-glycoprotein I antibodies (anti-β2GPI), while anti-cardiolipin 
antibodies (aCL) titre significantly decreased. While on treatment, anti-β2GPI and aCL levels 
both turned negative in Patient#2. Interestingly, after being on belimumab for one year, she 
planned a pregnancy and preferred to suspend the treatment, after 8 months since 
suspension, antiβ2GPI antibodies were detectable again. Patient#3 was persistently 
negative for aCL while being on belimumab(28 months). When he discontinued the therapy 
for lack of response, aCL antibodies returned positive after 2 months.   Figure 1 illustrates 
aPL titres of the three patients in relationship with belimumab therapy.Two patients (#1 and 
#3) persistently tested positive for LA despite Belimumab treatment. No patients 
experienced hypogammaglobulinemia while on belimumab and IgG/IgM levels were 
constantly within normal range. Of note, none of the patients was started on a concomitant 
immunossupressive treatment when Belimumab was begun. However, a synergic role of 
hydroxycloroquine in the aCL and anti-beta2GPI disappearance cannot be excluded. 
 
Persistent aPL disappearance is a hot topic of discussion in the field of APS, but the clinical 
significance of sero-negativization is still to be elucidated[7,8].At the best of our knowledge, 
despite its limitations (e.g. sample size and retrospective design), this pilot studyis the first 
report of aPL negativization after starting therapy with belimumab. Even more interesting, 
after stopping the treatment (mean time of two months) patients turned to be positive 
tested for IgG aPL again. The clinical relevance of these findings should be investigated in 
prospective multicenter studies, but if confirmed, they might modify the therapeutic 
management of APS patients.Potentially, the current ‘anti-thrombotic’ approach to APS 
patients will be at least combinedin the future with an‘immunomodulatory’ approach. 
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Table 1. Characteristics of the patients included in the study 
 
Sex Age Diagnosis 
Associated 
Autoimmune 
Disease 
aPLpositivity 
APS 
ClinicalEvents 
Indication for 
starting 
belimumab 
 
Concomitant 
immunomodula
nt treatment 
 
Previous 
Immunomodul
anttreatment 
Patient
#1 
M 51 APS SLE 
LA, aCLIgG,  
anti-β2GPI IgG 
Sub-
poplitealarter
ialthrombosis 
 
Cutaneus*(face
, upper trunk, 
arms) and 
articular 
involvement** 
 
 
Low doses of 
steroids (5 
mg/dl) and HCQ 
 
IVIG, high doses 
of steroids  
Patient
#2 
F 33 APS SLE 
aCL IgG,  
anti-β2GPI IgM 
3 
miscarriages  
<10th week of 
gestation 
Haematological
*** and 
articular 
involvement** 
 
Low doses of 
steroids (5 
mg/dl) and HCQ 
 
MMP,  high 
doses of 
steroids, IVIG, 
AZA 
Patient
#3 
M 39 APS SLE LA, aCLIgG 
3 episodes of 
DVT, severe 
thrombocyto
penia 
Haematological
**** 
involvement 
 
Low doses of 
steroids (5 
mg/dl) 
 
High doses of 
steroids, RTX 
and CYC 
 
APS –Antiphospholipid Syndrome; SLE – Systemic Lupus Erythematosus; aPL – 
antiphospholipid antibodies; LA- Lupus Anticoagulant; aCL- anticardiolipin antibodies; β2GPI- 
anti-β2Glycoprotein I antibodies; DVT – Deep Vein Thrombosis; HCQ –
hydroxychloroquine;IVIG, intravenous immunoglobulin; AZA, azathioprine; Rituximab, RTX; MMP, 
Mycophenolate; CYC, Cyclophosphamide, CYC.  
 
*Defined as Annular scaly plaques, hypopigmentation; scaly erythematous patches, 
reticulate erythema 
**Defined asinflammatory arthritis involving more than 3 joints 
***Defined as thrombocytopenia (<100.000 platelets X109/L), leucopenia(<2.500 white 
blood cells X109/L) and anemia (Hemoglobin <9g/dL) 
**** Defined as thrombocytopenia (<50.000 platelets X109/L), and leucopenia(<3.000 white 
blood cells X109/L 
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